Eli Lilly and Company (LILY34) — Capital Reinvestment Ratio
Eli Lilly and Company (LILY34) has a Capital Reinvestment Ratio of 0.47x as of March 2026, meaning it reinvests 0% of its operating cash flow (R$5.33 Billion) in capital expenditures (R$2.53 Billion). Check LILY34 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Eli Lilly and Company Capital Reinvestment Ratio (2014–2025)
This chart tracks Eli Lilly and Company's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see LILY34 operating cash flow.
Annual Capital Reinvestment Ratio for Eli Lilly and Company (2014–2025)
Year-by-year Capital Reinvestment Ratio for Eli Lilly and Company from 2014 to 2025. See Eli Lilly and Company (LILY34) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (BRL) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | R$16.81 Billion | R$10.85 Billion | ▼ -32.3% |
| 2024 | 0.95x | R$8.82 Billion | R$8.40 Billion | ▼ -7.4% |
| 2023 | 1.03x | R$5.71 Billion | R$5.88 Billion | ▲ +293.1% |
| 2022 | 0.26x | R$7.08 Billion | R$1.85 Billion | ▲ +45.1% |
| 2021 | 0.18x | R$7.26 Billion | R$1.31 Billion | ▼ -42.2% |
| 2020 | 0.31x | R$6.50 Billion | R$2.03 Billion | ▲ +11.6% |
| 2019 | 0.28x | R$4.84 Billion | R$1.35 Billion | ▼ -48.8% |
| 2018 | 0.55x | R$5.52 Billion | R$3.02 Billion | ▲ +41.8% |
| 2017 | 0.39x | R$5.62 Billion | R$2.16 Billion | ▲ +71.2% |
| 2016 | 0.23x | R$4.85 Billion | R$1.09 Billion | ▼ -37.4% |
| 2015 | 0.36x | R$2.96 Billion | R$1.07 Billion | ▲ +37.9% |
| 2014 | 0.26x | R$4.46 Billion | R$1.16 Billion | — |